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Background:There is little epidemiologic data on sepsis, particularly in areas of low antibi-
otic resistance. Here we report a prospective observational study of severe sepsis and
septic shock in patients admitted to the Intensive Care Unit (ICU) at Karolinska University
Hospital, Sweden. We aimed to evaluate short- and long-term mortality, and risk factors for
sepsis-related death. A second aim was to investigate patient care in relation to gender.
Methods: One hundred and one patients with severe sepsis and septic shock, admitted to
the ICU between 2005 and 2009, were prospectively enrolled in the study. Defined primary
endpoints were day 28, hospital, and 1-year mortality. Risk factors for sepsis-related death
was evaluated with a multivariate analysis in a pooled analysis with two previous sepsis
cohorts. In the subset of patient admitted to the ICU through the emergency department
(ED), time to clinician evaluation and time to antibiotics were assessed in relation to gender.
Results: In the septic cohort, the day 28, hospital, and 1-year mortality rates were 19,
29, and 34%, respectively. Ninety-three percent of the patients received adequate antibi-
otics from the beginning. Multi-resistant bacteria were only found in three cases. Among
the 43 patients admitted to the ICU through the ED, the median time to antibiotics was
86 min (interquartile range 52–165), and overall 77% received appropriate antibiotics within
2 h. Female patients received antibiotics significantly later compared to male patients
(p=0.047).
Conclusion: The results demonstrate relatively low mortality rates among ICU patients
with severe sepsis/septic shock, as compared to reports from outside Scandinavia. Early
adequate antibiotic treatment and the low incidence of resistant isolates may partly explain
these findings. Importantly, a gender difference in time to antibiotic therapy was seen.
Keywords: severe sepsis, septic shock, mortality, gender, antibiotics
INTRODUCTION
Despite better understanding of the pathophysiology and
improved management of sepsis, severe sepsis, and septic shock,
the incidence continues to increase (1–5). The mortality rates still
remain unacceptably high, ranging from 31 to 61% in multicentre
trials of septic shock (6–10).
Efforts have been made during the past decade to develop
protocols for management, in analogy with the previous evo-
lution of standardized care of other acute medical conditions
like myocardial infarction and multitrauma (11–14). An outcome
benefit is associated with early diagnosis and structured resusci-
tation of patients with severe sepsis and septic shock, i.e., Early-
Goal-Directed-Therapy (EGDT) (12, 15, 16). Elapsed time from
triage and qualification for EGDT to administration of appro-
priate antimicrobials are primary determinants of mortality in
patients with severe sepsis and septic shock (17). Kumar et al. (18)
reported that correct and rapid administration of adequate antibi-
otics significantly reduces mortality rates, with each hour of delay
in antimicrobial administration over the ensuing 6 h being associ-
ated with an average decreased survival of 7.6%. However, it was
recently emphasized that in patients who received antibiotics after
shock recognition, there is no increase in mortality associated with
a delay in antibiotics administration (19).
Levy et al. (20) recently reported a significant difference
between the USA and Europe in unadjusted mortality in severe
sepsis/septic shock patients. Importantly, this difference disap-
peared when adjusting for severity of illness, emphasizing the
complexity in interpreting results from different sites. Several fac-
tors including among others regional health care approaches as
well as access to care, age, and comorbid disease burden will
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all influence outcome. In Scandinavian countries lower mortal-
ity rates are commonly reported, for instance in the Finnsepsis
study the Intensive Care Unit (ICU), hospital, and 1-year mortality
rates in severe sepsis were 15.5, 28.3, and 40.9%, respectively (21).
The Finnsepsis study group also reported low mortality rates in
community-acquired septic shock with ICU and hospital mortali-
ties of 22 and 35%, respectively (22). In Norway, hospital mortality
in severe sepsis and septic shock were 27 and 29%, respectively
(23). Likewise, we have in our previous studies on biomarkers
in sepsis observed a relatively low day 28 mortality rate of 15.6
and 26% in severe sepsis and septic chock (24, 25). The Scandi-
navian countries share a beneficial antibiotic susceptibility setting
that allows for studies of clinical outcome in severe infections not
complicated by antibiotic resistance.
The aim of this paper was to investigate day 28, hospital, and 1-
year mortality in a prospective study of hospital and community-
acquired severe sepsis and septic shock patients treated in an ICU
in a Swedish University Hospital, and to evaluate risk factors for
sepsis-related death. A second aim was to investigate patient care in
the emergency department (ED), in particular time to antibiotics
and time to clinician evaluation in relation to gender.
MATERIALS AND METHODS
STUDY SETTING AND PATIENT COHORTS
In this prospective observational cohort study, a total of 101
patients were included in the septic cohort during the study period
from October 2005 to June 2009. Inclusion criteria were a diagno-
sis of severe sepsis or septic shock within the last 24 h in patients
admitted to the mixed medical and surgical ICU (12 beds) of
Karolinska University Hospital Huddinge, a tertiary care facil-
ity. Because of hospital sub-specialization in Stockholm County,
the Karolinska University hospital in Huddinge does not admit
multi-trauma patients and patients with elective lower GI, tho-
racic, or brain surgery are operated elsewhere. In the septic cohort,
43 patients were admitted to the ICU through the ED, allow-
ing for evaluation of immediate patient care. Identification and
enrollment of patients was performed by a research nurse dur-
ing day-time, Monday to Friday recruitment, which explains the
inclusion of patients over an extended period of time.
Severe sepsis and septic shock, including the clinical variables
were defined according to the criteria proposed by the Ameri-
can College of Chest Physicians/Society of Critical Care Medicine
(26). The diagnosis of sepsis required a clinical assessment of
infection together with systemic inflammatory reaction. Systemic
inflammatory reaction was defined by at least two of the following
criteria: fever or hypothermia (temperature >38.0 or <36.0°C,
respectively), tachycardia (heart rate >90 beats/min), tachypnea
(respiratory rate >20 breaths/min, or PaCO2 <32 torr (4.3 kPa)
or the requirement of mechanical ventilation),and white blood cell
count>12× 109/L (or>10% immature white blood cells). Severe
sepsis was defined as sepsis in addition to signs of acute reduction
of organ perfusion (not related to primary septic focus or underly-
ing chronic disease) as manifested by at least one of the following:
(a) acute deterioration of mental status; (b) arterial hypoxemia
[PaO2 <75 torr (10 kPa) without evidence of primary lung dis-
ease]; (c) oliguria (urine production <0.5 mL/kg/h for >2 h); (d)
acute deterioration of liver function (S-bilirubin >43µmol/L, or
S-alanine transaminase more than twice elevated above reference
value; (e) metabolic acidosis (plasma lactate elevated above nor-
mal levels or base excess ≥5 mEq/L); or (f) recent coagulation
abnormality (prothrombin time or activated partial thromboplas-
tin time ≥1.2 times the upper limit plus D-dimer ≥0.5 mg/L or
platelets ≤75× 109/L or a 50% reduction in 24 h). Septic shock
was defined as severe sepsis in addition to hypotension requir-
ing vasopressor support, or mean arterial pressure<70 mmHg for
≥30 min despite adequate fluid resuscitation.
In addition to the prospective cohort above, we also included
sepsis patients enrolled in two previous prospective studies as a
confirmatory cohort for comparison of mortality rates. These
studies had similar or identical inclusion criteria and were con-
ducted at the same study site between 1998 and 2001 (n= 54; 22
severe sepsis and 32 septic shock) and 2003 and 2005 (n= 50; 9
severe sepsis and 41 septic shock) (24, 25).
The study was conducted in accordance with the declaration
of Helsinki and was approved by the local ethics committee of
Karolinska University Hospital. Written informed consent was
obtained from the patients or their close relatives, and are archived
by the authors.
DATA COLLECTION AND OUTCOMES
Blood samples were collected from all patients and controls at
inclusion (0 h). Tubes were immediately centrifuged at 3000 rpm
for 10 min and aliquots of plasma were stored at −70°C until
analysis. Standard laboratory analyses were performed at the Clin-
ical chemistry laboratory, Huddinge, according to the manufac-
turer’s instructions.
Clinical data, including variables specified in Table 1, were
registered according to a predesigned Case Record Form daily
for all patients until day 7. Severity of disease was measured by
Acute Physiology and Chronic Health Evaluation (APACHE) II
(27) at admittance and also by daily Sepsis-related Organ Failure
Assessment (SOFA) scores until day 7 (28). These scores and final
diagnoses were determined retrospectively, on the basis of com-
plete patient charts and laboratory tests. The results of blood and
microbiological cultures were recorded.
The primary outcomes studied were day 28 mortality, in-
hospital mortality (death during hospital stay), and 1-year mortal-
ity. The outcomes were further compared with the above described
independent cohorts. The multivariate regression analysis for risk
factors of death in severe sepsis and septic shock was performed
and the survival rate was further analyzed in groups stratified by
age. We also retrospectively registered adequate antibiotic treat-
ment (determined based on comparison between administered
antibiotics and blood culture findings and/or diagnosis) and the
presence of multi-resistant bacteria defined as Extended Spectrum
Beta Lactamase (ESBL) or other multi-resistant Gram-negatives,
Vancomycin Resistant Enterococci (VRE), or Meticillin Resistant
Staphylococcus aureus (MRSA). We retrospectively studied the tim-
ing of antibiotic administration and clinician evaluation in those
patients that were admitted to the ICU through the ED (n= 43)
and performed a comparison based on gender. At Karolinska
University Hospital the exact time (hours:minutes) of the above
specified factors as well as time of admission is recorded in the
electronic patient chart.
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Table 1 | Baseline patient characteristics and laboratory findings in total cohort, and survivors vs. non-survivors.
Variable Septic cohort*, n=101 Survivors, n=82 Non-survivors, n=19 p-Value
GENDER, AGE
Male, n (%) 55 (55) 43 (52) 12 (63) 0.452
Age, median (range) 64 (23–89) 64 (23–89) 64 (45–86) 0.449
SEVERITY OF DISEASE, MEAN±SD
SOFA 0 h 10±3.4 9.6±3.2 11.6±4.1 0.054
SOFA 24 h 8.9±3.7 8.3±3.6 11.7±2.8 0.0004
SOFA 96 h 5.2±3.9 5.2±3.5 5.4±5.5 0.767
APACHE II 22.7±8.0 21.0±7.4 26.7±9.8 0.016
ACQUISITION OF INFECTION, n (%)
Community 62 (61) 51 (62) 11 (58) 0.796
Hospital 39 (39) 31 (38) 8 (42) 0.796
UNDERLYING CONDITIONS, n (%)
Previously healthy, n (%) 11 (11) 9 (11) 2 (11) 1.0
Diabetes 16 (16) 13 (16) 3 (16) 1.0
Smoking 15 (15) 10 (12) 5 (42) 0.151
Alcohol abuse 11 (11) 7 (9) 4 (21) 0.212
History of cancer 31 (31) 22 (27) 9 (47) 0.100
Immunosuppressiona 27 (27) 19 (23) 8 (42) 0.146
Hypertension 24 (24) 23 (28) 1 (5) 0.038
Heart diseaseb 21 (21) 17 (21) 4 (21) 1.0
Pulmonaryc 3 (3) 3 (4) 0 (0) 0.573
Liver diseased 8 (4) 4 (5) 4 (21) 0.039
Neurologic diseasee 5 (5) 3 (4) 2 (11) 0.236
Renal failure 4 (4) 3 (4) 1 (5) 0.572
Other diseasesf 15 (15) 12 (15) 3 (16) 1.0
Blood cultures (n=92) 76 16
Confirmed positive (%) 50 (54) 40 (53) 10 (63) 0.585
CLINICAL MANIFESTATIONS, n (%)
Pneumonia 25 (28) 17 (21) 8 (80) 0.075
Urinary tract infection 16 (16) 14 (17) 2 (10) 0.729
Intra-abdominal infection 42 (42) 36 (44) 6 (60) 0.440
Skin/soft tissue infection 9 (9) 7 (9) 2 (10) 0.676
Neutropenia 4 (4) 3 (4) 1 (5) 0.572
Bacterial meningitis 3 (3) 3 (4) 0 (0) 1.0
Undefined origin 2 (2) 2 (2) 0 (0) 1.0
LABORATORY FINDINGS, MEDIAN (IQR)
C-reactive protein (mg/L) 226 (140–308) 227 (143–316) 210 (89–276) 0.224
WBC (109/L) 14.3 (5.6–23.7) 14.3 (5.9–21.9) 13.6 (0.9–27.2) 0.664
Hemoglobin (g/L) 105 (92.5–117.5) 104.5 (96.5–118) 106 (99–113) 0.651
Platelet count (109) 165 (82–265) 171.5 (83–266) 126 (66–213) 0.262
P-glucose (mmol/L) 7.0 (6.1–8.9) 7.1 (6.4–9.0) 6.4 (4.5–7.3) 0.031
aPTT (s) 46 (40.5–56) 45.5 (40–53.3) 52 (44–62) 0.082
Creatinine (µmol/L) 155 (89–246.5) 153 (86–250) 163 (108–225) 0.357
Bilirubin (µmol/L) 18 (9–30.5) 16 (8–30) 23 (15–54) 0.058
INR 1.4 (1.2–1.8) 1.4 (1.2–1.7) 1.6 (1.2–2.7) 0.043
D-dimer (mg/L) 1.9 (0.8–3.9) 1.5 (0.8–3.7) 3.3 (1.4–7.2) 0.063
Lactate (mmol/L) 3.2 (2.2–5.2) 3 (2.1–4.0) 7.6 (2.8–11.1) 0.004
*Septic cohort consisted of 86 patients with septic shock and 15 patients with severe sepsis.
aAccording to APACHE II criteria.
bA history of heart disease contains of coronary artery disease and congestive heart failure.
cChronic obstructive pulmonary disease or emphysema or asthma.
dLiver disease contains of hepatitis with or without cirrhosis and primary biliary cirrhosis.
eNeurologic diseases: previous stroke and multiple sclerosis.
fInflammatory bowel disease, rheumatoid arthritis, psychiatric disease, ventricular ulcer, or hypothyreos.
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STATISTICAL ANALYSIS
Descriptive data are presented as mean (SD) for continuous data,
and medians with interquartile ranges (IQRs) for numerous data
that did not follow Gaussian distribution. To test for normal-
ity, we used recommended D’Agostino and Pearson omnibus
normality test. Comparisons between groups were made by the
non-parametric Mann–Whitney U test, or for categorical values,
Fisher’s exact test. A two-tailed p-value <0.05 was considered
statistically significant. The survival analysis was made by using
Kaplan–Meier survival curve. The analysis of risk factors for death
in the septic cohort was performed using a multivariate cox regres-
sion analysis performed in two steps. In the first step, univariate
analyses were performed for demographic and clinical factors
listed in Table 3. All factors with a univariate p-value of <0.1 were
entered into a stepwise Cox regression model where the model
selection was based on the Akaike Information Criteria (AIC)
approach. The GraphPad Prism 5 (GraphPad Software, La Jolla)
was used for all statistical analyses except the multivariate analysis
where the R version 2.14.1 was used.
RESULTS
PATIENTS: CLINICAL AND MICROBIOLOGICAL CHARACTERISTICS
After final classification, 86 patients with septic shock and 15
patients with severe sepsis were included in the study, i.e., a total
number of 101 patients referred to as the septic cohort.
Clinical characteristics and laboratory findings are presented
in Table 1. In each group of patients, the majority (>89%) had
underlying medical conditions, such as a history of cancer, car-
diac disease, and diabetes. In addition to cardiovascular shock,
49% of septic shock patients had kidney failure, 84% had respi-
ratory failure, and 15% had coagulation abnormalities. All septic
shock patients were put on vasopressor support, 93% were on
insulin therapy at study inclusion, and four patients were treated
with intravenous immunoglobulin adjunctive therapy. Thirty-
eight patients were immunosuppressed according to APACHE II
criteria. High-dose cortisone (i.e., exceeding a dose of 1000 mg
of hydrocortisone daily) was given to only one patient with sep-
tic shock, whereas 73% of septic shock and 60% of severe sepsis
patients received low dose cortisone (50–200 mg of hydrocortisone
three to four times daily). The median ICU and hospital length of
stays were 5 and 26 days, respectively, in the septic cohort.
The most prevalent underlying causes of severe sepsis and sep-
tic shock were abdominal infections, pneumonia, and urosepsis
(Table 1), which together represented 82% of the septic cohort.
Five patients had infections of undefined origin.
In all patients with severe sepsis and septic shock, blood cul-
tures were taken in 92 out of the 101 patients and 49% of
these were culture-positive. The highest frequency of blood cul-
tures were obtained in patients with urinary tract infections
(88% positive cultures), skin/soft tissue infections (77% posi-
tive cultures), and intra-abdominal infections (36% positive cul-
tures). There was an overrepresentation of Gram-negative bacteria
(59%) as compared to Gram-positive bacteria (41%), consistent
with abdominal origin being the most prevalent source of infec-
tion. Escherichia coli was the pathogen most commonly isolated
(Table 2), predominantly from patients with urinary tract or intra-
abdominal infections. Etiology was established in another 38 cases
Table 2 | Microbiological findings of blood cultures.
Organism No. isolates (n=49)
Escherichia coli 18
Staphylococcus aureus (MSSAa) 5
Klebsiella pneumonia 3
Pseudomonas 3
Streptococcus pneumonia 3
Serratia marcescens 2
Enterococcus faecalis 7
Proteus mirabilis 1
Candida 1
Corynebacterium 1
Clostridium septicum 1
Peptostreptococci 1
Neisseria meningitides 1
Staphylococcus epidermidis 1
G+ coccib 1
aMSSA, meticillin-susceptible S. aureus.
bNot possible to identify further.
through alternative microbiological cultures and serology. Four-
teen patients in the septic cohort lacked conclusive microbiological
diagnosis.
In relation to microbiological findings or diagnosis, 93% of
patients with severe sepsis or septic shock received adequate
antibiotic treatment. Seven patients received suboptimal antibiotic
treatment in relation to subsequent culture findings, but none of
these had multi-resistant bacteria (i.e., ESBL, other multi-resistant
Gram-negatives, VRE, or MRSA). Of the 101 patients in our sep-
tic cohort, only 2 had positive blood cultures of ESBL producing
bacteria (E. coli), 1 had VRE, and 2 had Serratia marcescens resis-
tant to Cefuroxim. The most common initial empiric antibiotic
treatment was carbapenems (60%), followed by cephalosporins
(20%), and piperacillin-tazobactam (13%). Twenty-three percent
received concurrent treatment with aminoglycosides. Adequate
antimicrobial therapy refers to empirical treatment on admit-
tance, at which time most patients did not have a microbiological
diagnosis. Many patients had postsurgical or hospital acquired
infections, for which carbapenems are recommended in Swedish
guidelines.
SHORT- AND LONG-TERMMORTALITY, AND RISK FACTORS FOR DEATH
The overall day 28 mortality rate was 19% in the septic cohort
and the hospital mortality was 29%. There were five additional
deaths after discharge in the septic cohort, yielding 1-year mor-
tality rate of 34%. Patients were stratified by age with a cut off
at 70 years. As expected, the elderly patients (n= 33 vs. 68 in the
younger group), had higher day 28, hospital, and 1-year mortality
compared with the younger group (21, 33, and 48 vs. 18, 26, and
26%) (Figure 1).
The day 28 non-survivors all died of septic shock with multiple
organ failure. The most common cause of death between days 28
and 365 was also a sustained septic shock with multiple organ fail-
ure followed by cardiac heart failure, pneumonia, cardiac arrest,
acute myocardial infarct, and liver failure.
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FIGURE 1 | Kaplan–Meier estimated survival in the septic cohort by age
(<70, or 70 years and older). (p-Value=0.021, log-rank test, χ2 =5.36).
Two previous studies with independent cohorts of 54 and 50
patients with severe sepsis and septic shock, enrolled at the same
site as the current study, reported low day 28 mortality rates
(24, 25). Here, we retrospectively calculated the hospital and 1-
year mortality of these previous cohorts. The hospital mortality
rate was 33% and the 1-year mortality rate was 41%, consis-
tent with our current study. Mortality rates in pooled data with
all three cohorts were 22% at day 28 (n= 45/205) and 38%
at day 365 (n= 77/205). The hospital mortality rate was 31%
(n= 62/205).
A multivariate regression analysis for risk factors of death in
severe sepsis and septic shock was performed using all patients
in the three sepsis cohorts (n= 205, septic shock n= 159, severe
sepsis n= 46). All independent factors with a p-value of <0.1
in the univariate analysis listed in Table 3 were included in the
multivariate analyses in which age, cardiac heart failure, immuno-
suppression, and SOFA score were shown to be independent risk
factors for death (Table 4).
PATIENTS WITH COMMUNITY-ACQUIRED SEVERE SEPSIS/SEPTIC
SHOCK ADMITTED TO THE ICU THROUGH THE ED
The septic cohort included 43 patients with community-acquired
severe sepsis and septic shock arriving to the ICU directly from
the ED (Table 5). This cohort was used to specifically assess
time to see a clinician and to antibiotic administration. In the
total cohort, the immediacy of fluid treatment was also registered.
Nine patients received pre-hospital (ambulance) fluid treatment.
The remaining 34 received fluid after a mean 46 min (range 0–
157 min), whereof 21% within 15 min, 47% within 30 min, and
71% of the patients within 60 min. Pre-ICU fluids consisted only
of crystalloids, colloids were only given in the ICU. Sixty-three
percent of the patients were assessed by a physician within 30 min,
98% within 60 min. The median time to first dose of antibi-
otic treatment was 86 min (IQR 52–165). Seventy-three percent
of the patients received antibiotic treatment within 2 h. Mor-
tality rates within each hour of antibiotic delay is shown in
Figure 2.
The analyses were also made according to gender, and as
shown in Table 5, the female patients were younger than the
male patients (p= 0.013) but were similar with respect to severity
Table 3 | Risk factors for negative outcome in severe sepsis and septic
chock*, univariate analysis with cox proportional hazards regression.
Hazard
ratio
Lower
limit
Upper
limit
p-Value
Gender 1.02 0.65 1.60 0.931
Age 1.03 1.01 1.04 0.003
Pneumonia 1.31 0.82 2.09 0.258
Abdominal infection 0.72 0.44 1.17 0.181
Urinary tract infection 0.70 0.32 1.53 0.377
Smoking 1.66 1.01 2.73 0.044
Alcohol 1.57 0.87 2.85 0.138
Diabetes 0.97 0.53 1.80 0.930
Coronary artery disease 0.67 0.31 1.46 0.314
Cardiac heart failure 1.97 1.04 3.74 0.037
Liver disease 2.02 1.07 3.83 0.031
Chronic obstructive lung disease 0.79 0.29 2.17 0.653
Immunosuppressiona 1.93 1.22 3.04 0.005
Lactate level 2.01 1.25 3.22 0.004
SOFA score (day 1) 1.17 1.10 1.25 <0.001
*Patients from the current study and the two pooled comparative cohorts of
severe sepsis and septic chock.
aAccording to APACHE II criteria.
Table 4 | Risk factors for negative outcome in severe sepsis and septic
shock*, multivariate stepwise cox regression analysis.
Hazard
ratio
Lower
limit
Upper
limit
p-Value
Age 1.02 1.00 1.04 0.019
Smoking 1.62 0.97 2.71 0.063
Cardiac heart failure 2.21 1.12 4.36 0.022
Liver disease 1.93 1.00 3.74 0.050
Immunosuppressiona 2.41 1.50 3.87 <0.001
Lactate 1.67 1.00 2.77 0.049
SOFA score (day 1) 1.12 1.05 1.20 0.001
*Patients from the current study and the two pooled comparative cohorts of
severe sepsis and septic shock.
aAccording to APACHE II criteria.
of disease, diagnosis, and comorbidities. In addition, no signifi-
cant difference in baseline cytokine levels were found, although
female showed slightly higher levels of all three cytokines. Female
patients waited for physician evaluation for a median time of
32 min (IQR 8–39 min) as compared to 12 min (IQR 4–35 min)
after admission to the ED for male patients (p= 0.22). In addi-
tion, female patients had a significantly delayed time to antibi-
otic treatment as compared to men, a median of 144 min (IQR
70–185) compared to 67 min (IQR 36–135 min; p= 0.0469)
(Figure 3A). Measuring time from physician assessment to
first dose of antibiotics, we found similar gender differences.
Women received the first dose at 101 min (IQR 66–140 min) as
compared to 52 min (IQR 25–96 min) for males (p= 0.0216)
(Figure 3B).
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Table 5 | Sepsis patients admitted to ICU through emergency department (ED): baseline patient characteristics in total cohort and in female vs.
male patients.
Variable Septic ED cohort*, n=43 Female, n=17 (40%) Male, n=26 (60%) p-Value
AGE
Age, median (range) 64 (23–89) 61 (26–76) 71 (23–89) 0.013
MORTALITY, n (%)
28-day mortality 8 (19) 4 (24) 4 (15) 0.692
1-year mortality 13 (30) 5 (29) 8 (31) 1.0
SEVERITY OF DISEASE, MEAN±SD
SOFA 0 h 10±3.3 9.9±3.8 10±3.1 0.970
APACHE II 24.1±8.5 22.3±8.9 25±8.2 0.249
UNDERLYING CONDITIONS, n (%)
Previously healthy, n (%) 11 (26) 3 (18) 8 (31) 0.480
Diabetes 7 (16) 2 (12) 5 (19) 0.685
Smoking 1 (2) 0 (0) 1 (4) 1.0
Alcohol abuse 7 (16) 2 (12) 1 (4) 0.685
History of cancer 10 (23) 5 (29) 5 (19) 0.481
Immunosuppressiona 10 (23) 5 (29) 5 (19) 0.481
Hypertension 14 (33) 5 (29) 9 (35) 1.0
Coronary artery disease 6 (14) 4 (24) 2 (8) 0.193
Chronic heart failure 3 (7) 1 (6) 2 (8) 1.0
CLINICAL MANIFESTATION, n (%)
Pneumonia 17 (40) 7 (41) 10 (38) 1.0
Urinary tract infection 11 (26) 6 (35) 5 (19) 0.296
Intra-abdominal infection 4 (9) 0 (0) 4 (15) 0.140
Skin/soft tissue infection 6 (14) 2 (12) 4 (15) 1.0
Neutropenia 1 (2) 1 (6) 0 (0) 0.395
Bacterial meningitis 1 (2) 1 (6) 0 (0) 0.395
Undefined origin 3 (7) 0 (0) 3 (12) 0.266
Time to see a physician, median (IQR) (min) 20 (5–35) 32 (8–39) 12 (4–35) 0.219
Time to adequate antibiotics from triage, median (IQR) (min) 86 (52–165) 144 (70–185) 67 (36–135) 0.047
CYTOKINES, MEDIAN (IQR)
IL-6 (pg/mL) 560 (106–3710) 1902 (120–6925) 477 (89–1373) 0.2097
IL-8 (pg/mL) 79 (31–1708) 200 (60–2362) 43 (23–890) 0.0729
IL-10 (pg/mL) 23 (9–67) 32 (9–248) 18 (9–53) 0.2912
*Septic cohort of 43 patients with 34 patients with septic shock and 9 patients with severe sepsis coming to the ICU through the ED.
aAccording to APACHE II criteria.
DISCUSSION
This prospective observational study of severe sepsis and septic
shock in a mixed medical and surgical ICU in a Swedish Univer-
sity Hospital is based on a septic cohort, which is comparable with
cohorts of previously reported international studies in respect to
severity of sepsis, defined by severity scores, age, and underlying
conditions (10, 18, 21). We report mortality rates of 19% (day
28), 29% (hospital), and 34% (1 year). Both short- and long-term
mortality was due to a septic shock with multiple organ failure
which in the late mortality cases were followed by cardiac heart
failure, pneumonia, cardiac arrest, acute myocardial infarct, and
liver failure. Risk factors for death were age, cardiac heart failure,
immunosuppression, and SOFA score. The noted mortality rates
are lower than that reported in the study by Kumar et al. (18), in
which the hospital mortality rate amounted to 56% in septic shock
patients, as well as in the study by Ranieri et al. (29) with a reported
day 28 mortality rate of 25.3%. Similarly, in an European multi-
centre study of septic shock patients (10), in which ages and SOFA
scores matched those of our study, the 28-day mortality rate was
33% and the hospital mortality rate was 43%. It is important to
highlight that our septic cohort includes 15% severe sepsis patients
whereas the others only had septic shock. However, inclusion of
only septic shock patients from our cohort resulted in even lower
mortality rates; day 28 mortality of 17% and hospital mortality
of 29%. Our mortality rates are in line with those reported from
Scandinavia such as in the Finnsepsis study (21).
As highlighted in the recent report by Levy et al. (20) many
factors influence mortality rates in different settings, not the least
different health care systems and approaches to critical care. In the
Stockholm area, clinical subspecialties are largely administratively
centralized to different hospitals, such as upper gastrointestinal
surgery for which Karolinska University Hospital Huddinge is the
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FIGURE 2 |Time to adequate antibiotics in hours, and relation to
mortality rate. The figure includes severe sepsis and septic shock patients
(n=43) admitted to the ICU directly from the emergency department.
FIGURE 3 | Gender differences in (A) time from triage to antibiotics
(p=0.047) and (B) time from seeing the physician to adequate
antibiotics (p=0.022). Statistically significant differences between the
groups were determined by the non-parametric Mann–Whitney U test. A
two-tailed p-value <0.05 was considered statistically significant and the
p-values are indicated. Horizontal lines denote median values.
main center; explaining the dominance of abdominal infections in
our study, withE. coli being the most prevalent pathogen. There are
few data related to the effects of different sources of infection on
outcome. It has previously been suggested that abdominal infec-
tions may be more severe (30, 31) than respiratory infections. A
recent study showed no differences in age, sex, severity score, or
mortality rates between the two groups, but the development of
septic shock, early coagulation, and acute renal failure was more
common in patients with abdominal infections (32). The fact that
abdominal infections dominate should, if anything, influence our
mortality rates negatively.
Many studies have shown that the prognosis of severe sep-
sis and septic shock can be improved by using internationally
recommended guidelines (33). The efficacy and speed of early
management and adequate treatment in the initial hours after
onset of illness are likely to influence outcome, in analogy with the
treatment of acute myocardial infarction or acute trauma. Early
Goal-Directed Therapy in severe sepsis and septic shock patients
has been shown to improve 1-year mortality rate compared to
standard treatment (34). Our 1-year mortality rate matches this
outcome although there was no explicit adherence to an EGDT
protocol. Importantly, the severity of disease in our septic shock
patients was higher (SOFA score 10.4± 3.4 vs. 7± 4) suggesting
that our patients were more severely ill compared to the patients in
the study of Puskarich et al. (34). National guidelines in Sweden, at
the time of the study recommended the use of low dose corticos-
teroids for septic shock patients in the need of inotropic support,
but is currently restricted to those with persisting hypotension
despite inotropic therapy. Seventy-three percent of our septic
shock patients received hydrocortisone, indicating underprescrip-
tion by guidelines at the time, but overprescription by current
standards. Overprescription likely had no effect on mortality (10).
Time to receive adequate antibiotics is a critical survival fac-
tor (18), in particular prior to shock recognition (19). In this
study, we report that the majority of patients received appropriate
antibiotics within 2 h, which is shorter than in many other studies
reporting 3 h or longer (19, 22). This, and the fact that 93% of
the patients in our cohort were given adequate antibiotics from
the onset could partly explain the low mortality rate. So far, Swe-
den has managed to contain antibiotic resistance (35, 36). It is
among the countries with the lowest rates of MRSA (<1%) and E.
coli-producing ESBL (<5%). First-line antibiotics still work – for
example, S. pneumoniae is routinely treated with penicillin G or V.
A troubling finding was the noted gender difference in time to
seeing a clinician and receiving adequate antibiotics, which could
not be explained by severity of disease, clinical presentation, diag-
noses, or inflammation (i.e., plasma cytokine levels at inclusions).
Previous studies have reported a potential impact of gender on
mortality in sepsis, but the results are inconsistent: some found a
higher risk in men (37), some in women (38), and some found
no difference (39). Here we report, for the first time, that gender
influences time to antibiotic treatment. Considering the strong
link between time to antibiotics and outcome of severe sepsis and
septic shock, this is a clinically important finding. In an attempt to
seek the underlying reason for this delay in treatment, the female
and male cohorts were compared with respect to diagnosis, eti-
ology, and severity of infection but no differences were identified
expect the fact that the females were younger. However it should
be noted that this subgroup analyses is based on a small patient
cohort and the results need to be verified in larger studies.
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In summary, the results demonstrate low mortality rates, both
short- and long-term, in this patient cohort despite high APACHE
II scores and presence of multiple comorbidities. A multivariate
analysis revealed that risk factors for a fatal outcome in sepsis was
age, cardiac heart failure, immunosuppression, and SOFA score.
Our low mortality rates may be explained by the combination of a
well-functioning triage system that directs the patient to the right
priority group, the presence of an Infectious Disease specialist both
in the ER and the ICU, the lack of resistant isolates and short-time
to adequate antibiotics together with early aggressive fluid resus-
citation. Although the majority of the patients received adequate
antibiotics from the beginning, the data suggested that women
with community-acquired severe sepsis and septic shock had a
delay in antibiotic treatment as compared to men; a concerning
observation that warrants further studies.
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